Contact: Colleen T. White
Optimum Relations Publiques
Franklin Lakes, NJ (June 10, 2008) — BD (Becton, Dickinson and Company), a leading global medical technology company, today celebrated the grand opening of its BD Diagnostics - GeneOhm manufacturing facility in Québec, Canada. With this new $34 million facility, BD is helping to meet the growing demand for diagnostic tests that provide rapid detection of bacterial organisms, including those known to cause healthcare-associated infections (HAIs). The 64,500-square-foot facility includes 30,200 square feet of new manufacturing space.
“BD built this facility to meet anticipated demand for BD GeneOhm™ products, which are critical tools for hospitals combating the growing HAIs problem,” said Vincent Forlenza, BD Executive Vice President. “Our expansion in Québec also establishes this location as the center of research and development for BD’s rapid molecular diagnostic products.”
The BD GeneOhm™ MRSA Assay delivers results in less than two hours and helps prevent and control HAIs. In contrast, traditional culture screening methods can take up to 72 hours. More than two million people around the world have been tested with the BD GeneOhm™ MRSA Assay, and its customer base has grown to more than 250 hospitals in the U.S., Canada, Europe and Asia-Pacific.
Located in Parc Technologique du Québec Métropolitain, BD’s new state-of-the-art facility has created 125 new jobs and is expected to add an additional 75 jobs total over the next two years. With BD’s new facility, the Parc Technologique now represents the largest concentration of life sciences businesses in Québec City.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.